Qube Research & Technologies (QRT)
NKTR icon

Qube Research & Technologies (QRT)’s Nektar Therapeutics NKTR Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.11M Sell
130,521
-260,154
-67% -$19M 0.01% 1343
2026
Q1 		$28.1M Buy
390,675
+66,760
+21% +$3.8M 0.03% 688
2025
Q4 		$13.7M Buy
323,915
+319,941
+8,051% +$17.9M 0.01% 1136
2025
Q3 		$226K Buy
+3,974
New +$132K ﹤0.01% 2915
2025
Q1 		– Sell
-4,384
Closed -$61.2K – 3747
2024
Q4 		$61.2K Buy
+4,384
New +$77.3K ﹤0.01% 3074
2024
Q3 		– Sell
-1,087
Closed -$20.2K – 3848
2024
Q2 		$20.2K Sell
1,087
-1,837
-63% -$38.7K ﹤0.01% 2881
2024
Q1 		$41K Buy
2,924
+1,195
+69% +$12.5K ﹤0.01% 3548
2023
Q4 		$14.7K Sell
1,729
-2,106
-55% -$16K ﹤0.01% 3547
2023
Q3 		$34.3K Sell
3,835
-21,392
-85% -$206K ﹤0.01% 2976
2023
Q2 		$218K Buy
+25,227
New +$269K ﹤0.01% 1752
2023
Q1 		– Sell
-3,628
Closed -$123K – 2865
2022
Q4 		$123K Buy
+3,628
New +$176K ﹤0.01% 1949
2022
Q3 		– Sell
-2,965
Closed -$169K – 2839
2022
Q2 		$169K Buy
+2,965
New +$187K ﹤0.01% 1771
2020
Q1 		– Sell
-1,877
Closed -$608K – 1479
2019
Q4 		$608K Buy
+1,877
New +$544K 0.02% 857
2019
Q3 		– Sell
-614
Closed -$328K – 388
2019
Q2 		$328K Buy
+614
New +$308K 0.08% 245
2019
Q1 		– Sell
-416
Closed -$205K – 457
2018
Q4 		$205K Sell
416
-32
-7% -$19.3K 0.09% 260
2018
Q3 		$410K Buy
+448
New +$382K 0.05% 270

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT)'s NKTR Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Nektar Therapeutics (NKTR) stake by 67% in Q2 2026, selling an estimated $19M and leaving 130,521 shares worth $9.11M. The position accounts for 0.01% of the portfolio, ranked #1343.

Qube Research & Technologies (QRT) first reported a position in NKTR in Q3 2018 and has held it in 16 quarters since. The position peaked at $28.1M in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Qube Research & Technologies (QRT) held 130,521 shares of Nektar Therapeutics worth $9.11M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 260,154 Nektar Therapeutics shares in Q2 2026, an estimated $19M.
  • Nektar Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1343 holding.
  • Qube Research & Technologies (QRT) first reported a position in Nektar Therapeutics in Q3 2018 and has held it in 16 quarters since.
  • Qube Research & Technologies (QRT)'s Nektar Therapeutics position peaked at $28.1M in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.